Francis X Guyette1, Jason L Sperry2, Andrew B Peitzman2, Timothy R Billiar2, Brian J Daley3, Richard S Miller4, Brian G Harbrecht5, Jeffrey A Claridge6, Tyler Putnam7, Therese M Duane8, Herb A Phelan9, Joshua B Brown2. 1. Department of Emergency Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA. 2. Division of General Surgery and Trauma, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA. 3. Department of Surgery, University of Tennessee Health Science Center, Knoxville, TN. 4. Department of Surgery, Vanderbilt University Medical Center, Nashville, TN. 5. Department of Surgery, University of Louisville, Louisville, KY. 6. MetroHealth Medical Center/Case Western Reserve University, Cleveland, OH. 7. University of Pittsburgh Medical Center, Altoona Hospital, Altoona, PA. 8. John Peter Smith Health Network, Fort Worth, TX. 9. Department of Surgery, University of Texas Southwestern/ Parkland Memorial Hospital, Dallas, TX.
Abstract
OBJECTIVE: The aim of this study was to determine whether prehospital blood products reduce 30-day mortality in patients at risk for hemorrhagic shock compared with crystalloid only resuscitation. SUMMARY OF BACKGROUND DATA: Hemorrhage is the primary cause of preventable death after injury. Large volume crystalloid resuscitation can be deleterious. The benefits of prehospital packed red blood cells (PRBCs), plasma, or transfusion of both products among trauma patients is unknown compared with crystalloid. METHODS: Secondary analysis of the multicenter PAMPer trial was performed on hypotensive injured patients from the scene. The trial randomized 27 helicopter bases to prehospital plasma or standard resuscitation. Standard resuscitation at the sites was equally divided between crystalloid and crystalloid + PRBC. This led to 4 prehospital resuscitation groups: crystalloid only; PRBC; plasma; and PRBC+plasma. Cox regression determined the association between resuscitation groups and risk-adjusted 30-day mortality. The dose effect of resuscitation fluids was also explored. RESULTS: Four hundred seven patients were included. PRBC+plasma had the greatest benefit [hazard ratio (HR) 0.38; 95% confidence interval (95% CI) 0.26-0.55, P < 0.001], followed by plasma (HR 0.57; 95% CI 0.36-0.91, P = 0.017) and PRBC (HR 0.68; 95% CI 0.49-0.95, P = 0.025) versus crystalloid only. Mortality was lower per-unit of PRBC (HR 0.69; 95% CI 0.52-0.92, p = 0.009) and plasma (HR 0.68; 95% CI 0.54-0.88, P = 0.003). Crystalloid volume was associated with increased mortality among patients receiving blood products (HR 1.65; 95% CI 1.17-2.32, P = 0.004). CONCLUSION: Patients receiving prehospital PRBC+plasma had the greatest mortality benefit. Crystalloid only had the worst survival. Patients with hemorrhagic shock should receive prehospital blood products when available, preferably PRBC+plasma. Prehospital whole blood may be ideal in this population.
OBJECTIVE: The aim of this study was to determine whether prehospital blood products reduce 30-day mortality in patients at risk for hemorrhagic shock compared with crystalloid only resuscitation. SUMMARY OF BACKGROUND DATA: Hemorrhage is the primary cause of preventable death after injury. Large volume crystalloid resuscitation can be deleterious. The benefits of prehospital packed red blood cells (PRBCs), plasma, or transfusion of both products among trauma patients is unknown compared with crystalloid. METHODS: Secondary analysis of the multicenter PAMPer trial was performed on hypotensive injured patients from the scene. The trial randomized 27 helicopter bases to prehospital plasma or standard resuscitation. Standard resuscitation at the sites was equally divided between crystalloid and crystalloid + PRBC. This led to 4 prehospital resuscitation groups: crystalloid only; PRBC; plasma; and PRBC+plasma. Cox regression determined the association between resuscitation groups and risk-adjusted 30-day mortality. The dose effect of resuscitation fluids was also explored. RESULTS: Four hundred seven patients were included. PRBC+plasma had the greatest benefit [hazard ratio (HR) 0.38; 95% confidence interval (95% CI) 0.26-0.55, P < 0.001], followed by plasma (HR 0.57; 95% CI 0.36-0.91, P = 0.017) and PRBC (HR 0.68; 95% CI 0.49-0.95, P = 0.025) versus crystalloid only. Mortality was lower per-unit of PRBC (HR 0.69; 95% CI 0.52-0.92, p = 0.009) and plasma (HR 0.68; 95% CI 0.54-0.88, P = 0.003). Crystalloid volume was associated with increased mortality among patients receiving blood products (HR 1.65; 95% CI 1.17-2.32, P = 0.004). CONCLUSION: Patients receiving prehospital PRBC+plasma had the greatest mortality benefit. Crystalloid only had the worst survival. Patients with hemorrhagic shock should receive prehospital blood products when available, preferably PRBC+plasma. Prehospital whole blood may be ideal in this population.
Authors: Alexander T Williams; Alfredo Lucas; Cynthia R Muller; Crystal Bolden-Rush; Andre F Palmer; Pedro Cabrales Journal: J Appl Physiol (1985) Date: 2020-06-18
Authors: Dan Levin; Maoz Zur; Eilat Shinar; Tzadok Moshe; Avishai M Tsur; Roy Nadler; Mark H Yazer; Danny Epstein; Guy Avital; Shaul Gelikas; Elon Glassberg; Avi Benov; Jacob Chen Journal: Transfus Med Hemother Date: 2021-10-06 Impact factor: 3.747
Authors: Norman F Luc; Nathan Rohner; Aditya Girish; Ujjal Didar Singh Sekhon; Matthew D Neal; Anirban Sen Gupta Journal: Platelets Date: 2021-08-30 Impact factor: 3.862
Authors: Sarah Ann Watts; Jason Edward Smith; Thomas Woolley; Rory Frederick Rickard; Robert Gwyther; Emrys Kirkman Journal: Eur J Trauma Emerg Surg Date: 2022-07-27 Impact factor: 2.374
Authors: Husayn A Ladhani; Vanessa P Ho; C Clare Charbonnet; Jason L Sperry; Francis X Guyette; Joshua B Brown; Brian J Daley; Richard S Miller; Brian G Harbrecht; Herb A Phelan; Jeffrey A Claridge Journal: J Trauma Acute Care Surg Date: 2021-08-01 Impact factor: 3.697
Authors: Carsten Lott; Anatolij Truhlář; Anette Alfonzo; Alessandro Barelli; Violeta González-Salvado; Jochen Hinkelbein; Jerry P Nolan; Peter Paal; Gavin D Perkins; Karl-Christian Thies; Joyce Yeung; David A Zideman; Jasmeet Soar Journal: Notf Rett Med Date: 2021-06-10 Impact factor: 0.826